The resolution to this paradox would be found in the third major paradigm shift, which revealed Fibroblast Growth Factor 23 (FGF23) as the dominant, and previously unrecognized, driver of cardiovascular risk in CKD. This evidence concerns the gene FGF23 and chronic kidney disease.